NRIX Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
9.0M
+44.6%
6.3M
-54.0%
13.6M
+72.0%
7.9M
-82.1%
44.1M
Cost of Revenue
0
0
0
0
0
Gross Profit
9.0M
+44.6%
6.3M
-54.0%
13.6M
+72.0%
7.9M
-82.1%
44.1M
Operating Expenses
103.2M
+4.6%
98.7M
+2.1%
96.7M
-2.6%
99.3M
+7.5%
92.4M
R&D
87.7M
+4.2%
84.1M
+1.3%
83.0M
-3.6%
86.1M
+10.3%
78.1M
SG&A
15.6M
+6.7%
14.6M
+7.0%
13.6M
+3.7%
13.2M
-7.9%
14.3M
Operating Income
-94204000
-1.8%
-92495000
-11.3%
-83095000
+9.1%
-91385000
-89.1%
-48322000
EBITDA
-91949000
-1.8%
-90299000
-11.5%
-80975000
+9.4%
-89357000
-93.9%
-46080000
Net Income
-89535000
-2.7%
-87174000
-11.4%
-78221000
+9.5%
-86421000
-98.8%
-43464000
EPS (Basic)
$-0.81
-2.5%
$-0.79
+3.7%
$-0.82
+20.4%
$-1.03
-98.1%
$-0.52
EPS (Diluted)
$-0.81
-2.5%
$-0.79
+3.7%
$-0.82
+20.4%
$-1.03
-98.1%
$-0.52
Shares (Diluted)
111.1M
+0.9%
110.1M
+15.8%
95.1M
+13.0%
84.2M
+0.3%
83.9M
Nurix Therapeutics (NRIX) โ€” Financials